Resmed Inc
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory d…
The business
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
Small Caps Research
No research on Resmed Inc yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise RMD based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Latest news
ResMed delivers double-digit EPS growth on increasing demand for sleep apnoea devices
ResMed (ASX: RMD) has reported double-digit earnings per share (EPS) growth for the three months to March on the back of increasing market demand for its best-in-class sleep apnoea products and software solutions. The company’s revenue for the period increased by 8% to US$1.3 billion (up 9% on a constant currency basis), while income from […]
ResMed shares hit as Eli Lilly’s weight loss drug demonstrates sleep apnoea benefits
Medical device maker ResMed (ASX: RMD) saw its shares tumble more than 13% after pharmaceutical rival Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) could also help resolve sleep apnoea in some patients. California-based ResMed is a giant in the sleep apnoea space, manufacturing face masks, nasal devices and continuous positive airway pressure (PAP) […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.